Meeder Asset Management Inc Amneal Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.02 - $3.62 $29,251 - $52,421	-14,481 Reduced 97.04%	442 $1,000
Q1 2022 May 10, 2022	BUY	$3.9 - $4.89 $58,199 - $72,973	14,923 New	14,923 $62,000
Q4 2021 Feb 11, 2022	SELL	$3.95 - $5.85 $66,261 - $98,133	-16,775 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$4.31 - $5.64 $1,176 - $1,539	273 Added 1.65%	16,775 $88,000
Q2 2021 Aug 09, 2021	BUY	$5.12 - $6.82 $75,187 - $100,151	14,685 Added 808.2%	16,502 $84,000
Q1 2021 Apr 28, 2021	BUY	$4.74 - $7.38 $8,612 - $13,409	1,817 New	1,817 $10,000
Q4 2020 Feb 09, 2021	SELL	$3.95 - $5.42 $47,242 - $64,823	-11,960 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$3.54 - $5.27 $37,934 - $56,473	-10,716 Reduced 47.26%	11,960 $47,000
Q2 2020 Aug 11, 2020	BUY	$2.87 - $5.46 $12,645 - $24,056	4,406 Added 24.12%	22,676 $109,000
Q1 2020 May 15, 2020	BUY	$2.46 - $5.35 $10,499 - $22,833	4,268 Added 30.48%	18,270 $64,000
Q4 2019 Feb 13, 2020	SELL	$2.65 - $5.56 $49,809 - $104,505	-18,796 Reduced 57.31%	14,002 $67,000
Q3 2019 Oct 17, 2019	BUY	$2.29 - $7.1 $69,222 - $214,618	30,228 Added 1176.19%	32,798 $94,000
Q2 2019 Aug 05, 2019	SELL	$6.44 - $14.29 $58,565 - $129,953	-9,094 Reduced 77.97%	2,570 $18,000
Q1 2019 Apr 16, 2019	BUY	$11.87 - $14.84 $122,818 - $153,549	10,347 Added 785.65%	11,664 $166,000
Q4 2018 Jan 17, 2019	SELL	$13.09 - $21.49 $132,117 - $216,898	-10,093 Reduced 88.46%	1,317 $18,000
Q3 2018 Nov 02, 2018	BUY	$16.4 - $24.27 $168,247 - $248,985	10,259 Added 891.31%	11,410 $0
Q2 2018 Jul 24, 2018	BUY	$13.95 - $20.2 $16,056 - $23,250	1,151 New	1,151 $0

185

141M

57K

49K

Ticker AMRX
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 151,408,992
Market Cap $1.25B
Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.